论文部分内容阅读
目的探讨苯巴比妥预防小儿惊厥复发的效果。方法将65例热性惊厥患儿随机分为治疗组38例,对照组27例,两组病例均给予常规退热及原发病治疗,治疗组在发热初期立即口服苯巴比妥5 mg/(kg.d),分为每8 h口服1次,至热退后停服,而对照组不给予任何镇静止痉药物。结果治疗组复发率15.9%,对照组为44.4%,差异有统计学意义(P<0.05)。结论间隙口服苯巴比妥预防小儿热性惊厥复发疗效很好,无明显不良反应,且口服方便,值得临床推广应用。
Objective To investigate the effect of phenobarbital in preventing relapse of pediatric convulsions. Methods A total of 65 children with febrile seizures were randomly divided into treatment group (38 cases) and control group (27 cases). Both groups were given routine antipyretic and primary treatment. The treatment group were given phenobarbital 5 mg / (kg · d), divided into oral once every 8 h, to withdraw from the heat to retreat, while the control group does not give any sedation antispasmodic drugs. Results The recurrence rate was 15.9% in the treatment group and 44.4% in the control group, the difference was statistically significant (P <0.05). Conclusion Gap oral phenobarbital is effective in preventing recurrence of pediatric febrile seizures. It has no obvious side effects and is convenient for oral administration. It is worthy of clinical application.